Stay updated on Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.

Latest updates to the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page
- Check6 days agoChange DetectedThe webpage has been updated to reflect a new phase II trial of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guérin (BCG) for high-risk T1 bladder cancer and high-grade NMI-UTUC, with significant changes in the trial's description and inclusion criteria.SummaryDifference43%
- Check13 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 17, 2025.SummaryDifference0.2%
- Check20 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe webpage has updated its contact information, replacing Dean Bajorin, MD with Gopakumar Iyer, MD, and has adjusted the relevant dates for updates and availability.SummaryDifference3%
- Check49 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check71 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.